Price
Target price
€23.19
€23.19
-14.840%
-3.97
-14.840%
-
26.06.26 / Tradegate
WKN: A2PLU4 / Name: Capricor / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Capricor Therapeutics Inc Stock
Heavy losses for Capricor Therapeutics Inc today as the stock fell by -€3.970 (-14.840%).
For the coming years our community has positive and negative things to say abot the Capricor Therapeutics Inc stock. Criterium "Return on equity" gathered the most positive votes but regarding "Return on equity" there were negative voices in the community.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | -14.840% | -6.454% | -8.013% | 166.246% | -9.591% | 399.784% | 395.513% |
| Heron Therapeutics Inc. | 2.100% | 2.700% | -49.519% | -79.761% | -66.535% | -64.495% | -97.319% |
| Evolus Inc | -1.830% | 8.316% | 14.558% | -21.006% | 12.330% | -9.971% | -45.339% |
| Rhythm Pharmaceuticals | -1.050% | 12.575% | 22.876% | 82.524% | 0.535% | 491.195% | 446.512% |
News
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Key Points
- Interested in Capricor Therapeutics, Inc.? Here are five stocks we like better.
- Capricor Therapeutics says it is in active discussions with the FDA to support approval of deramiocel
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), exercised 25,000 options for common stock and immediately sold the resulting shares for a transaction value of
